Navigation Links
Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
Date:5/19/2008

ve tissue of the joints and in the kidneys, leading to inflammation, the formation of disfiguring nodules (tophi), intermittent attacks of severe pain (acute flares), and kidney damage (nephropathy). While gout is a treatable condition, there are limited treatment options, and a number of adverse effects are associated with current therapies. No new therapies have been approved by the FDA for the treatment of hyperuricemia associated with gout in the past 40 years.

About RDEA594

RDEA594 is a development candidate that has potential for treating gout patients with hyperuricemia. RDEA594 is a metabolite of RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of HIV. In Phase 1 studies with RDEA806 in healthy volunteers, increased urinary excretion of uric acid was observed in the first 24 hours after dosing, with statistically significant, exposure-dependent, decreases in serum uric acid of 35% to 50% observed following 10-14 days of dosing. RDEA594 exhibits a concentration-dependent inhibitory effect on the URAT1-mediated uptake of uric acid ex vivo and is believed to be the active moiety responsible for the uric acid-lowering effects of RDEA806. Approximately 90% of hyperuricemic patients are considered to be under-excretors of uric acid, so increasing excretion may provide the most physiologically appropriate treatment. RDEA594 does not have significant antiviral activity.

About Ardea Biosciences

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evalu
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
2. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
3. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
4. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
5. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
10. Neurocrine Biosciences Reports First Quarter 2008 Results
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 26, 2015 Research and Markets( ... Pacific Portable X Ray Devices Market - Growth, Trends And ... The Asia Pacific market ... healthy CAGR from 2014 to 2020 X-Ray is ... the abnormalities in the body, especially bones. The need of ...
(Date:5/27/2015)... FORT WORTH, Texas , May 27, 2015 /PRNewswire/ ... report defines and segments the concerned market with analysis ... reach $1,017.8 million by 2019 and is estimated to ... to 2019. Browse through the TOC of ... an idea of the in-depth analysis provided. This report ...
(Date:5/27/2015)... , May 26, 2015 Research and Markets( ... "Asia Pacific Fluoroscopy Market - Growth, Trends And Forecasts ... The Asia Pacific ... healthy CAGR from 2014 to 2020 Fluoroscopy ... real-time moving images of the interior of the body. ...
Breaking Medicine Technology:Asia Pacific Portable X Ray Devices Market 2015 - Trends And Forecasts to 2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 3Asia Pacific Fluoroscopy Market Trends and Forecasts 2014 - 2019 2
... 2011 Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ... clinical and preclinical data highlighting the safety and efficacy ... New Phase 3 data on the ... after augmentation mammoplasty will be presented by Sergio Bergese, ...
... 5, 2011 Xlumena, Inc., a ... endoscopist and endoscopic surgeon, announced today that it ... AXIOS™ Stent and Delivery System (AXIOS). The AXIOS ... translumenal therapy and is indicated for drainage of ...
Cached Medicine Technology:Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations 2Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations 3Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations 4Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations 5Xlumena Receives CE Mark for Revolutionary AXIOS™ Stent and Delivery System 2
(Date:5/27/2015)... 27, 2015 With the launch of ... robust Network Management Module (NMM) tool, monitoring provider-network adequacy ... issue of Atlantic Information Services, Inc.’s (AIS) Medicare Advantage ... tool, as well as analysis from industry experts on ... changes coming to the NMM were announced at CMS’s ...
(Date:5/27/2015)... 2015 While hair transplantation has been ... new pilot study conducted by a physician member of ... found hair follicle grafting can help treat patients with ... funded by ISHRS, which offers research grants for the ... , In the past decade, numerous scientific studies ...
(Date:5/27/2015)... In today's healthcare landscape, where costs are ... challenging for doctors and hospitals to keep up with ... Austin-based HealthTronics, Inc. is offering a solution ... for clinically sophisticated applications. The company has now broadened ... Laser Ventures, Inc ., a mobile laser technology company ...
(Date:5/27/2015)... Marcos, CA (PRWEB) May 27, 2015 Allred ... solution to help patients - who need extensive dental treatment ... well as treatment options customized for their problems. , Dr. ... in a visual presentation of the assessment of the patient’s ... suitable options, which can treat their oral health problems. , ...
(Date:5/27/2015)... May 27, 2015 Dr. Omar Ibrahimi, ... in Stamford, CT has been selected as part of ... physicians nationwide (and the only physician in Connecticut) to ... allows for the removal of submental fat (double chin). ... recovery time, no surgery and minimal risks. Dr. Ibrahimi ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 3Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:San Marcos Dentistry Office Offering a New Service Dental Case Planning 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3
... Jerrold ... Connolly Medical Ltd. , ... (Vocus) January 29, 2010 -- Berkeley Heights – Jerrold S. Lozner, M.D., M.H.A., ... named as a “Top Doctor for Women’s Health” by Castle Connolly Medical, Ltd, in ...
... Pa. , Jan. 29 The Susan P. ... educate and inspire people of all ages to make healthy ... as President and CEO.  A talented non-profit leader, his goal ... expanding the delivery and distribution of health education services by ...
... , , Provides oral regime for hormone ... SPRING, Md. , Jan. 29 The U.S. ... with Femara (letrozole) to treat hormone positive and HER2-positive advanced ... indicated. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , HER2 ...
... respiratory weakness as a factor in the morbidity of ... that could improve long-term patient outcomes while reducing costs ... chair of research for the Department of Internal Medicine ... awarded a highly competitive, two-year, $480,000/year NIH Challenge Grant ...
... ... Following is the National Council on Disability,s monthly bulletin for December ... NCD,s award-winning Web site ( http://www.ncd.gov ), brings you the latest issues ... go to http://listserv.access.gpo.gov , click on "Online mailing list archives," select ...
... HANOVER TOWNSHIP, Pa. , Jan. 29 During a ... Secretary Everette James and Secretary of Education Gerald ... activity among middle school students. , "One-third of all Pennsylvania ... a lifetime of health problems," said James. "Schools like Hanover ...
Cached Medicine News:Health News:Summit Medical Group Physician Named 'Top Doctor for Women's Health' 2Health News:Susan P. Byrnes Health Education Center Names C.T. O'Donnell President and CEO 2Health News:Susan P. Byrnes Health Education Center Names C.T. O'Donnell President and CEO 3Health News:FDA Expands Use of Approved Breast Cancer Drug 2Health News:FDA Expands Use of Approved Breast Cancer Drug 3Health News:Kentucky research looks at respiratory weakness in ICU morbidity 2Health News:National Council on Disability Monthly Bulletin for January 2010 2Health News:National Council on Disability Monthly Bulletin for January 2010 3Health News:National Council on Disability Monthly Bulletin for January 2010 4Health News:National Council on Disability Monthly Bulletin for January 2010 5Health News:National Council on Disability Monthly Bulletin for January 2010 6Health News:National Council on Disability Monthly Bulletin for January 2010 7Health News:National Council on Disability Monthly Bulletin for January 2010 8Health News:National Council on Disability Monthly Bulletin for January 2010 9Health News:State Health, Education Leaders Applaud Luzerne County School for Boosting Physical Activity Among Students 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: